Evidence map›Paper›PMID 38283067›Full record

ArticleFrontiers in aging neuroscience2023

From theory to practice: translating the concept of cognitive resilience to novel therapeutic targets that maintain cognition in aging adults.

Andrea R Zammit, David A Bennett, Aron S Buchman

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrea R ZammitRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, United States.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, United States.
Aron S BuchmanRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, United States.

Funding

EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Identifying resilience proteins in key motor tissues that drive motor and cognitive decline and offset the negative effects of ADRD pathologies within and outside the brainR01AG075728 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARON S BUCHMAN · 2022 to 2026
$6.9M
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathologyR01AG053446 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL, URIBARRI, JAIME · 2016 to 2021
$3.8M
Thinking about walking: Can digital phenotyping of mobility improve the prediction of Alzheimer's dementia and inform on the pathologies and proteins contributing to this association?R01AG079133 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARON S BUCHMAN · 2022 to 2026
$3.5M
NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG053446NIA NIH HHS R01 AG075728NIA NIH HHS R01 AG079133
6 · The paper itself

Abstract

While the concept of cognitive resilience is well-established it has not been defined in a way that can be measured. This has been an impediment to studying its underlying biology and to developing instruments for its clinical assessment. This perspective highlights recent work that has quantified the expression of cortical proteins associated with cognitive resilience, thus facilitating studies of its complex underlying biology and the full range of its clinical effects in aging adults. These initial studies provide empirical support for the conceptualization of resilience as a continuum. Like other conventional risk factors, some individuals manifest higher-than-average cognitive resilience and other individuals manifest lower-than-average cognitive resilience. These novel approaches for advancing studies of cognitive resilience can be generalized to other aging phenotypes and can set the stage for the development of clinical tools that might have the potential to measure other mechanisms of resilience in aging adults. These advances also have the potential to catalyze a complementary therapeutic approach that focuses on augmenting resilience via lifestyle changes or therapies targeting its underlying molecular mechanisms to maintain cognition and brain health even in the presence of untreatable stressors like brain pathologies that accumulate in aging adults.

Indexed as

cognitive agingcognitive declinecognitive resiliencemolecular mechanismsneuropathology

Identifiers

PMID38283067
PMCPMC10811007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.